CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026
BioSpace
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
pharminent
May 6, 2026 (Last updated: May 6, 2026)
BioSpace
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
